Company: ARTL
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001640334-25-002022
Chunk: 1

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
4,267  $4,698 

 3Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except per share data)

  Three Months Ended  Nine Months Ended   September 30,  September 30,   2025  2024  2025  2024              OPERATING EXPENSES            General and administrative $1,814  $870  $4,088  $2,779 Research and development  1,275   325   4,530   3,517 Total operating expenses  3,089   1,195   8,618   6,296                  Loss from operations  (3,089)  (1,195)  (8,618)  (6,296)                 OTHER INCOME (EXPENSE)                Interest income  5   -   13   - Interest expense  (111)  -   (183)  - Net change in fair value of digital assets  75   -   75   - Net change in fair value of trading marketable securities  -   63   -   248 Total other income (expense)  (31)  63   (95)  248                  Provision for income taxes  -   -   -   -                  NET LOSS $(3,120) $(1,132) $(8,713) $(6,048)                 OTHER COMPREHENSIVE INCOME (LOSS)                Foreign currency translation adjustments  18   (15)  (75)  (15)Total other comprehensive income (Loss)  18   (15)  (75)  (15)                 TOTAL COMPREHENSIVE LOSS $(3,102) $(1,147) $(8,788) $(6,063)                 Basic and diluted loss per share of common stock $(3.97) $(2.10) $(12.48) $(11.28)                 Basic and diluted weighted average of shares of